Evaluating the effectiveness of the eHealth-faciLitated SMILe-integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies.

In 30 seconds

Two multicentre, hybrid effectiveness-implementation randomised controlled trials at European allogeneic stem cell transplantation (alloSCT) centres evaluated SMILe-ICM, an eHealth-supported, advanced practice nurse-led self-management intervention, against usual care in 152 adult recipients. The intervention group reported lower treatment burden across five dimensions. Cumulative incidence of acute graft-versus-host disease (GvHD) was 34.2% vs. 55.3% (HR 0.54, 95% CI 0.33-0.88; p = 0.01). Health-related quality of life improved in both groups without significant between-group differences, and chronic GvHD did not differ significantly. The acute GvHD result is an association requiring further investigation.

Key findings

• Treatment burden was lower with SMILe-ICM, with significant differences in five dimensions.
• Cumulative incidence of acute GvHD was 34.2% vs. 55.3% (HR 0.54, 95% CI 0.33-0.88; p = 0.01).
• Health-related quality of life improved over time in both groups, without significant between-group differences.
• Chronic GvHD did not differ significantly between groups (p = 0.64).

Why it matters

Treatment burden is an important patient-reported outcome after alloSCT, and these trials suggest that integrated, nurse-led support with eHealth may help reduce it. The lower acute GvHD incidence is a potentially relevant clinical signal, but the abstract does not establish how the intervention might influence this outcome. Together, the findings broaden evaluation beyond feasibility and implementation outcomes.

What to keep in mind

The acute GvHD result is a secondary outcome and the authors state that further investigation is needed to clarify whether and through which pathways the intervention may affect clinical outcomes.